We’ve announced that our initial data shows 100% disease control in 5 out of 5 patients with recurrent glioblastoma after being treated with our ANKTIVA, NK cell therapy plus the Optune Gio® device. Read more: immunitybio.com/initial-data-s…
00:00
ImmunityBio, Inc.
940 posts
ImmunityBio, Inc.
@ImmunityBio
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen patients’ natural immune system to fight cancer.
- Thrilled about the news that our partners Drs. Hotez and Bottazzi have been nominated for the Nobel Prize for their work on low-cost #COVID-19 vaccine that’s already in use in India. Congratulations on the well-deserved recognition! @TexasChildrens @PeterHotez @mebottazzi
- The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow, Dr. Fred Ramsdell, and Dr. Shimon Sakaguchi, recipients of the 2025 Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of
- We've announced our new study, called COVID-4.019-Long, which further expands our clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: ir.immunitybio.com/news-releases/…
00:00 - We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: immunitybio.com/immunitybio-re…
00:00 - We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield™ platform, anchored by ANKTIVA®, to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed
00:00 - We’ve announced new paradigm-changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer
00:00 - At ImmunityBio, we're redefining cancer care. Our mission focuses on developing treatments that are not only effective, but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment, offering hope through innovative
- Today, we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent, ANKTIVA® (nogapendekin alfa inbakicept-pmln), in combination with Bacillus
00:00 - Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system, facilitating the attack and elimination of cancerous or infected cells today while building
00:00 - We’ve reported a 60% revenue increase in Q2 2025, with year-to-date sales reaching $43M and a 246% growth in ANKTIVA® sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: immunitybio.com/immunitybio-re…
00:00 - Dr. Patrick Soon-Shiong presented groundbreaking insights on harnessing NK cells and memory T cells to fight urological cancers today at the #AUA2025 Innovation Nexus. We’re honored to collaborate with healthcare professionals in advancing treatments for bladder cancer.
- ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it. View our pipeline: immunitybio.com/pipeline/
00:00 - We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield™ platform to Saudi Arabia and the broader Middle East. Learn more:
